Shetty, Sharashchandra
Swaminathan, Aparna C. https://orcid.org/0000-0002-0003-9971
Li, Peide
Neely, Megan L. https://orcid.org/0000-0002-0101-1081
Olson, Amy L https://orcid.org/0000-0002-5368-0412
Snyder, Laurie D. https://orcid.org/0000-0002-5962-2184
,
Baker, Albert
Bandyopadhyay, Debabrata
Beegle, Scott
Belperio, John A.
Chardon, Domingo
Condos, Rany
Dilling, Daniel
Bemiss, Bradford
Fitzgerald, John
Flaherty, Kevin R.
Fowler, Reginald
Gulati, Mridu
Gupta, Nishant
Case, Amy Hajari
Hamblin, Mark
Hotchkin, David
Kaner, Robert J.
Kebbe, Jad
Kim, Hyun J.
Gupta, Ena
Hewlett, Justin
Lasky, Joseph A.
Sanchez, Hector
Pinto-Plata, Victor
Lipchik, Randolph
Lobo, LJason
Luckhardt, Tracy R.
Mageto, Yolanda
Maher, Toby M.
Morrison, Lake
Namen, Andrew
Paul, Tessy
Porteous, Mary
Raj, Rishi
Ramaswamy, Murali
Roman, Jesse
Rosas, Ivan
Russell, Tonya
Safdar, Zeenat
Liu, Gabrielle
Southern, Brian
Strek, Mary E.
Veeraraghavan, Srihari
Walia, Rajat
Whelan, Timothy P. M.
Funding for this research was provided by:
The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers.
Article History
Received: 19 March 2026
Accepted: 9 May 2026
First Online: 27 May 2026
Declarations
:
: SS, ALO and PL are employees of Boehringer Ingelheim Pharmaceuticals, Inc. ACS, MLN and LDS are faculty members of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to run the IPF-PRO/ILD-PRO Registry.
: The study was approved by the Duke University Institutional Review Board (Pro00046131) and at every enrolling center (listed in the Acknowledgments). The protocol was approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrollment at every site. All patients provided written consent prior to entering the registry.
: All patients provided written informed consent.
: Not applicable.